FDA Approved: SENSIPAR — Supplemental Application (Amgen Inc)

View source ↗

Summary

The FDA approved a supplemental application for SENSIPAR (cinacalcet hydrochloride) from Amgen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercalcemia Due to Parathyroid Carcinoma
• Hyperparathyroidism

Drugs mentioned

• SENSIPAR (CINACALCET HYDROCHLORIDE)

Snippet

SUPPL AP for SENSIPAR (CINACALCET HYDROCHLORIDE)